Ruplizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ruplizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD154
Clinical data
Trade names Antova
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NYesY (what is this?)  (verify)

Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2]

References[edit]

  1. ^ Liossis, SN; Sfikakis, PP (2004). "Costimulation blockade in the treatment of rheumatic diseases". BioDrugs. 18 (2): 95–102. PMID 15046525. doi:10.2165/00063030-200418020-00003. 
  2. ^ Nakamura, M; Tanaka, Y; Satoh, T; Kawai, M; Hirakata, M; Kaburaki, J; Kawakami, Y; Ikeda, Y; Kuwana, M (2006). "Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism". Rheumatology (Oxford, England). 45 (2): 150–6. PMID 16188945. doi:10.1093/rheumatology/kei118.